TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Out-patients with active rheumatoid arthritis (RA), according to the ACR 1987 revised criteria, with low to moderate disease activity (DAS28-ESR ≥ 2.6 and ≤ 5.1)~2. Patients must be on stable doses of methotrexate (MTX) ≥ 7.5 and ≤ 25 mg/week for at least 12 weeks before the first injection, with appropriate folic acid supplementation~3. Age ≥ 18 years at Screening~4. Body weight at least 50 kg at Screening; BMI: ≥ 18.0 and ≤ 30.0 kg/m2 at Screening~5. Negative tuberculosis test at Screening~6. Heterosexually active male and female patients of childbearing potential are obliged to follow whatever contraceptive and / or breastfeeding restrictions may be required for their concomitant medication(s), including methotrexate.~In addition, heterosexually active male and female patients of childbearing potential are required to use effective double-method contraception (one hormonal contraceptive or intrauterine device and one other additional contraceptive method) for 1 month before the first administration of the IMP, during the course of the trial, and for 6 month after the last injection of MT203.~No special requirements are made for female patients proven to be post-menopausal (at least 2 years after last menstrual period and FSH ≥ 40IU/L), surgically sterilized or hysterectomized. Likewise no special requirements for heterosexually active male who are surgical sterilized.~Pregnant or lactating female patients have to be excluded.~Exclusion Criteria:~1. Participation in another clinical trial or previous dosing in this trial~2. Use of specified medications within certain timeframes or use of certain comedications~3. History or presence of specified diseases~4. Drug abuse~5. Certain laboratory parameters outside a specified range~6. Donation of blood~7. Relevant decrease in lung function~8. Infections, frequent or chronic infections, herpes zoster~9. Females: positive pregnancy test~10. Presence of history of tuberculosis~11. History of malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Namilumab 150 mg (Type: EXPERIMENTAL): Namilumab (MT203) 150 mg (low dose), subcutaneous (SC) injection, on Days 1, 15 and 29.
- Namilumab 300 mg (Type: EXPERIMENTAL): Namilumab (MT203) 300 mg (high dose), SC injection, on Days 1, 15 and 29.
- Placebo (Type: PLACEBO_COMPARATOR): Namilumab-matching placebo, SC injection, on Days 1, 15 and 29.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by DSM-IV-TR criteria~2. Outpatient status at last visit of Trial 331-10-230 or Trial 331-10-231~3. Willing to discontinue all prohibitive psychotropic medications to meet protocol required washouts prior to and during the trial period.~4. Other protocol specific inclusion criteria may apply.~Exclusion Criteria:~1. Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug~2. Subjects with a current DSM-IV-TR Axis I diagnosis of:~   * Schizoaffective disorder~  * MDD~  * Bipolar disorder~  * Delirium, dementia, amnestic or other cognitive disorder~  * Borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder~3. Subjects presenting with a first episode of schizophrenia~4. Other protocol specific exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- OPC-34712 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent obtained before starting any study-specific procedure.~2. Symptomatic elderly MM newly diagnosed by EBMT criteria older than 65 years.~3. Performance status (ECOG) ≤ 2.~4. Have pre-treatment clinical laboratory values meeting the following criteria within 14 days of randomization:~   * platelet count ≥ 75x109/L~  * haemoglobin ≥ 8g/dL~  * absolute neutrophil count (ANC) ≥ 1.0x109/L~  * Serum bilirubin ≤ 1.5 mg/dL and alkaline phosphatise ≤ 2.5 x ULN AST, ALT ≤ 2.5 x ULN~  * Serum creatinine ≤2,5 mg/dl~Exclusion Criteria:~1. Patient previously received treatment with Velcade or Revlimid.~2. Patient previously received treatment for Multiple Myeloma.~3. Patient has ≥ Grade 2 peripheral neuropathy within 14 days before enrolment.~4. Patient has hypersensitivity to bortezomib, boron, mannitol or lenalidomide.~5. Patient has received other investigational drugs with 28 days before enrolment.~6. Patient had a myocardial infarction within 6 months of enrolment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.~7. Patient currently is enrolled in another clinical research study and/or is receiving an investigational agent for any reason.~8. Radiation therapy within 30 days before randomization, at least patient has had antialgic radiation. Radiation therapy will be afterwards permitted during the treatment period if it is indicated due to the presence of plasmacytomas

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MPV followed by Revlimid/Low Dose Dexamethasone (Rd) (Type: ACTIVE_COMPARATOR): Melphalan/Prednisone/Velcade (MPV) followed by Revlimid/Low Dose Dexamethasone (Rd)
- Alternating MPV with Revlimid/Low Dose Dexamethasone (Type: EXPERIMENTAL): Alternating Velcade/Melphalan/Prednisone (MPV) with Revlimid/Low Dose Dexamethasone (Rd)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female subjects 18 years or older~2. Diagnosis of multiple myeloma~3. Measurable, secretory multiple myeloma defined as serum monoclonal IgG of ≥10 g/L, serum monoclonal IgA or IgE ≥5 g/L, or serum monoclonal IgD ≥0.5g/L; or urine M-protein of ≥200 mg/24 hr~4. Relapse or progression of myeloma following prior systemic antineoplastic therapy.~Exclusion Criteria:~1. Previous treatment with VELCADE~2. More than 3 previous lines of therapy (separate lines of therapy are defined as single or combination therapies that are either separated by disease progression or by a greater than 6 month treatment-free interval)~3. Peripheral neuropathy or neuropathic pain of NCI CTCAE Grade ≥2~4. Any of the following within 3 weeks prior to randomization:~   antineoplastic or experimental therapy, corticosteroid use above 10mg a day (prednisone or equivalent), or plasmapheresis~5. Any of the following within 2 weeks prior to randomization:~   radiation therapy, major surgery (kyphoplasty is not considered major surgery)~6. Prior malignancy other than multiple myeloma diagnosed or treated within the last 2 years, with the exception of completely resected carcinoma in situ or basal/squamous carcinoma of the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): VELCADE administered by subcutaneous injection
- 2 (Type: ACTIVE_COMPARATOR): VELCADE administered by intravenous infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Subjects diagnosed with type 2 diabetes and treated with one or more oral antidiabetic drugs (OADs) for the last 3 months~* HbA1c: 7.0-11.0% (both incl.) for subjects on OAD alone~* HbA1c: 7.0-10.0 % (both incl.) for subjects on OAD combination therapy~* BMI less than 45.0 kg/m\^2~Exclusion Criteria:~* Treatment with insulin within the last 3 months prior to the trial~* Impaired liver or/and renal function~* Significant cardiovascular disease over the last 6 months~* Known retinopathy or maculopathy~* Recurrent major hypoglycaemia or hypoglycaemic unawareness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Lira 0.6 + Met (Type: EXPERIMENTAL): Liraglutide 0.6 mg + metformin + glimepiride placebo
- Lira 1.2 + Met (Type: EXPERIMENTAL): Liraglutide 1.2 mg + metformin + glimepiride placebo
- Lira 1.8 + Met (Type: EXPERIMENTAL): Liraglutide + metformin + glimepiride placebo
- Glim + Met (Type: EXPERIMENTAL): Glimepiride 4.0 mg + metformin + liraglutide placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Paracetamol, Dexketoprofen Trometamol, Lidocaine Spray, Pethidine and Diclofenac Sodium Application for Pain Relief During Fractional Curettage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* multiparous participants~* abnormal uterine bleeding~* postmenopausal bleeding~* myoma uteri causing menometrorrhagia~* cervical polyp~* tamoxifen treatment for breast cancer~* adnexial mass~Exclusion Criteria:~* abortions~* pregnancy~* primiparity~* diabetes mellitus~* tendency to bleed such as thrombocytopenia~* factor deficiency~* functional disorders of platelets

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Control group (Type: NO_INTERVENTION): Control group
- Pain reliever (Type: ACTIVE_COMPARATOR): 1000 mg paracetamol (Parol 1 g Atabay ilaç Turkey)
- Dexketoprofen trometamol (Type: ACTIVE_COMPARATOR): 25 mg oral Dexofen Atabay ilaç Turkey
- Lidocaine spray (Type: ACTIVE_COMPARATOR): 2 puff on cervical mucosa (Xylocain Pump 100 Mg 50 Ml Sprey Astra Zeneca)
- pethidine (Type: ACTIVE_COMPARATOR): Aldolan 100 mg Liba Laboratuarı İstanbul Turkey
- diclofenac sodium (Type: ACTIVE_COMPARATOR): Dicloron amp 75 mg Deva İlaç Levent İstanbul/Turkey

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SRL (Sirolimus) Withdrawal

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male and female recipients of all races, ≥ 18-75 years of age~2. Patients who underwent primary living or deceased donor liver transplantation ≥ 3 years (previous to screening ) and on ≥ 3 months of stable SRL monotherapy~3. Recipient of single organ transplant only~4. Liver transplant for non-immune, non-viral (no hepatitis B or hepatitis C virus unless currently non-viremic) causes~5. Ability to provide informed consent and to comply with the study protocol of IS withdrawal.~Exclusion Criteria:~1. Inability or unwillingness to provide informed consent~2. Acute cellular rejection within 12 months prior to enrollment~3. Viral (viremic hepatitis B virus \[HBV\] or hepatitis C virus \[HCV\]) or immune-mediated liver disease (Autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cirrhosis) history~4. Abnormal liver function tests: Direct bilirubin ≥ 1 mg/dL; (\[ALT, AST, GGT\] or alkaline phosphatase \[AlkPhos\] ≥ 2x \[ULN\]); 5) Abnormal graft histology at enrollment: a) ≥ Grade 2 inflammation or stage 2 fibrosis; b) Acute or Chronic Rejection; c) De-novo Autoimmune Hepatitis; d) inflammation of \>50% of portal tracts; e) Other pathology not-specified but deemed high risk per the PI and pathologist; 6) Ongoing or recurrent substance abuse~7) Retransplantation or combined liver-other organ 8) Human Immunodeficiency Virus(HIV) co-infection 9) Glomerular Filtration Rate (GFR)\<30 ml/min by estimated glomerular filtration rate (\[eGFR\]-\[MDRD-4\])

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Single-arm study Sirolimus Withdrawal (Type: EXPERIMENTAL): SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sodium-Restricted Diet and Diuretic in the Treatment of Severe Sleep Apnea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men in the age range from 18 to 60 years~* Full-night in-laboratory polysomnography with apnea-hypopnea index \> 30/h in the last three months~* Body mass index \< 35 kg/m2~* Informed consent~Exclusion Criteria:~* Already having started any treatment for sleep apnea, including use of continuous positive airway pressure~* NYHA heart failure, any class~* Predominantly central apnea~* Peripheral venous or lymphatic insufficiency~* Any chronic renal disease~* Use of diuretics and substances with action in the central or peripheral nervous system such as benzodiazepines, hypnotics, anticonvulsants, antidepressants, appetite suppressants, amphetamines, antiparkinson agents, muscle relaxants, bronchodilators~* Stroke within 6 months or with incapacitating sequelae~* Any physical, mental or social condition impairing the ability to participate in the trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Lasilactone (Type: ACTIVE_COMPARATOR): Dosage form: One capsule taking in the morning Dosage: furosemide, 20mg, and spironolactone, 100 mg. Frequency and duration: One capsule daily for 7 days.
- placebo pill (Type: PLACEBO_COMPARATOR): One capsule taking in the morning. Frequency and duration: One capsule daily for 7 days.
- Sodium-Restricted Diet (Type: ACTIVE_COMPARATOR): The diet group will receive a regimen with a prescribed intake of three grams of sodium per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Supported Employment: Motivational Enhancement for Entry and Outcome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible to receive VA services~* Diagnosis of serious mental illness: schizophrenia, schizoaffective, psychosis NOS, bipolar disorder, or depression with psychotic features~* Currently unemployed~* Not currently enrolled in Supported Employment services~* Expects to stay within 100 miles of Bedford, MA for the next 18 months~* Has a significant other (friend or family member) who is also willing to participate (a criterion required only from March 2011 to March 2012 of the recruitment period)~Exclusion Criteria:~* Currently in prison~* Not able to provide informed consent~* Not able to speak and understand English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adapted Motivational Interviewing (AMI) (Type: EXPERIMENTAL): Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
- Support and Education for Recovery (SER) (Type: PLACEBO_COMPARATOR): Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Warming Device During Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Plastic surgery lasting approximately 5 hours~* Subjects over the age of 18 years~* Patient signed Informed Consent~Exclusion Criteria:~* Plastic surgery lasting less than 5 hours~* Individuals under the age of 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1: Bair Hugger (Type: None): Intraoperative warming with Bair Hugger forced air system
- 2: Hot Dog (Type: None): Intraoperative warming with Hot Dog resistive heating system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 10 to ≤ 17 years of age (before 18th birthday)~* Diagnosis of heterozygous familial hypercholesterolemia~* On an approved statin with stable optimized dose for ≥ 4 weeks~* Other lipid-lowering therapy stable for ≥ 4 weeks (fibrates must be stable for ≥ 6 weeks)~* Fasting LDL-C ≥ 130 mg/dL (3.4 mmol/L)~* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)~Exclusion Criteria:~* Type 1 diabetes, or type 2 diabetes that is or poorly controlled~* Uncontrolled hyperthyroidism or hypothyroidism~* Cholesterylester transfer protein (CETP) inhibitor in the last 12 months, or mipomersen or lomitapide in the last 5 months~* Previously received evolocumab or any other investigational therapy to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9).~* Lipid apheresis within the last 12 weeks prior to screening.~* Homozygous familial hypercholesterolemia

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Matching subcutaneous injection every 4 weeks (QM)
- EvoMab 420 mg QM (Type: EXPERIMENTAL): Evolocumab subcutaneous injection QM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CROSSOVER
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male aged ≥45 years;~* Experienced abrupt visual change in only 1 eye~Exclusion Criteria:~* Pain determined by an ophthalmologist to be consistent with an inflammatory/arteritic process or optic neuritis;~* History of NAION or optic neuritis.~* Participation in other studies within 60 days prior to entry in the study.

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Case Group (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete